Taking people in GermanyPhase 2
Tests brenipatide against placebo in adults with uncontrolled moderate to severe asthma
Tests brenipatide against a placebo in adults with uncontrolled asthma.
Key facts
- Who runs it
- Eli Lilly & Co.
- Where
- Bendorf, Berlin, Essen, Frankfurt am Main, Hamburg, Leipzig, Mainz, and Offenbach, GermanySee the 9 sitesAlso in 3 other countries, 20 sites
- Trial code
- EU 2025-522640-41-00
- U1111-1325-5672
- Registry title
- A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 137 people, planned
- Started
- 13 Feb 2026
- Expected to end
- 16 Jun 2028
- Type of study
- Interventional
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with asthma that is not well controlled, who have been on a controller medicine and had a severe attack needing steroid tablets in the past year.
- Age
- 18 to 64 years
- Sex
- Women and men can join.
- Disease stage
- Asthma diagnosed by a doctor, uncontrolled, moderate to severe. At least 1 severe asthma attack that needed oral steroid treatment in the 12 months before screening.
- Earlier treatment
- Must have taken an asthma controller medicine prescribed by a doctor for at least 12 months before screening.
Main reasons for not taking part
- Asthma caused by work (job-related asthma)
- A lung condition other than asthma, such as smoker's lung or a long-lasting infection that did not go away completely
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants must have been diagnosed with asthma and have received an asthma controller medication prescribed by their doctor for at least 12 months prior to screening
- Participants must have a history of 1 severe asthma exacerbation that led to oral steroid treatment in the last 12 months prior to screening
Who cannot take part
- Participants must not have a Lung condition other than asthma, such as smoker’s lung, infections that has been going on for a long time or didn’t go away completely
- Participants must not have a Diagnosis of job-related asthma
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Germany
Also in 3 other countries, 20 sites
- KPPK GmbHBendorf, GermanyTaking people
- Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbRBerlin, GermanyTaking people
- Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbHEssen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- IKF Pneumologie GmbH & Co. KGFrankfurt am Main, GermanyTaking people
- ME Clinical Respiratory Research Hamburg GmbHHamburg, GermanyTaking people
- POIS Sachsen GmbHLeipzig, GermanyTaking people
- IKF Pneumologie GmbH & Co. KGMainz, GermanyTaking people
- Dedicated Research Site FutureMedsOffenbach, GermanyTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of brenipatide relative to placebo in reducing severe asthma exacerbations
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
- Plain-language title
- Tests brenipatide against placebo in adults with uncontrolled moderate to severe asthmaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-522640-41-00, who can take part
- Record updated
- 26 August 2026